Sanofi SA (SNY)
46.68
-1.00
(-2.10%)
USD |
NASDAQ |
Apr 24, 16:00
46.68
0.00 (0.00%)
After-Hours: 20:00
Sanofi Research and Development Expense (TTM): 7.283B for Dec. 31, 2023
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 7.283B |
| September 30, 2023 | 7.131B |
| June 30, 2023 | 7.069B |
| March 31, 2023 | 7.058B |
| December 31, 2022 | 7.050B |
| September 30, 2022 | 6.998B |
| June 30, 2022 | 6.952B |
| March 31, 2022 | 6.870B |
| December 31, 2021 | 6.725B |
| September 30, 2021 | 6.401B |
| June 30, 2021 | 6.177B |
| March 31, 2021 | 6.362B |
| June 30, 2020 | 6.349B |
| March 31, 2020 | 6.643B |
| December 31, 2019 | 6.737B |
| September 30, 2019 | 6.783B |
| June 30, 2019 | 6.969B |
| March 31, 2019 | 6.948B |
| December 31, 2018 | 6.947B |
| September 30, 2018 | 6.756B |
| June 30, 2018 | 6.634B |
| March 31, 2018 | 6.367B |
| December 31, 2017 | 6.189B |
| September 30, 2017 | 6.015B |
| June 30, 2017 | 5.802B |
| Date | Value |
|---|---|
| March 31, 2017 | 5.752B |
| December 31, 2016 | 5.720B |
| September 30, 2016 | 5.525B |
| June 30, 2016 | 5.668B |
| March 31, 2016 | 5.600B |
| December 31, 2015 | 5.545B |
| September 30, 2015 | 5.682B |
| June 30, 2015 | 5.695B |
| March 31, 2015 | 5.947B |
| December 31, 2014 | 6.200B |
| September 30, 2014 | 6.180B |
| June 30, 2014 | 6.228B |
| March 31, 2014 | 6.147B |
| December 31, 2013 | 6.114B |
| September 30, 2013 | 6.398B |
| June 30, 2013 | 6.262B |
| March 31, 2013 | 6.300B |
| December 31, 2012 | 6.309B |
| September 30, 2012 | 6.264B |
| June 30, 2012 | 6.559B |
| March 31, 2012 | 6.698B |
| December 31, 2011 | 6.666B |
| September 30, 2011 | 6.682B |
| June 30, 2011 | 6.358B |
| March 31, 2011 | 6.097B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
6.177B
Minimum
Jun 2021
7.283B
Maximum
Dec 2023
6.797B
Average
6.870B
Median
Mar 2022
Research and Development Expense (TTM) Benchmarks
| AstraZeneca PLC | 10.94B |
| GSK PLC | 7.747B |
| Novo Nordisk A/S | 4.708B |
| Regeneron Pharmaceuticals Inc | 4.439B |
| Inhibrx Inc | 191.64M |